A Randomized, Double-Blind, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg QD When Added to Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)-Inhibitor Therapy

Trial Profile

A Randomized, Double-Blind, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg QD When Added to Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)-Inhibitor Therapy

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Nov 2017

At a glance

  • Drugs Bempedoic acid (Primary)
  • Indications Hypercholesterolaemia
  • Focus Therapeutic Use
  • Sponsors Esperion Therapeutics
  • Most Recent Events

    • 06 Nov 2017 Planned End Date changed from 31 Mar 2018 to 30 Jun 2018.
    • 06 Nov 2017 Status changed from recruiting to active, no longer recruiting.
    • 26 Jul 2017 According to an Esperion Therapeutics media release, top-line results from the study are expected by the first quarter of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top